Tailored Phone Calls Increased Rate of Genetic Testing, Counseling for Hereditary Cancer Risk

March 2, 2023 9:44 am

by Alison Kanski

NEW YORK – Personalized phone discussions about genetic risk assessment increased the number of breast and ovarian cancer patients who got genetic testing or discussed their risk with a genetic counselor, a study from Rutgers Cancer Institute … Read more

Study yields insights into patient perceptions of cancer clinical trial benefits, burdens

February 1, 2023 2:09 pm

by Jennifer Byrne

Patient withdrawal from cancer clinical trials can result in systematic bias, insufficiently powered studies and a loss of valuable scientific knowledge, according to a study in JAMA Network Open.

Although increased attention has been paid to … Read more

Avutometinib Plus Defactinib Generates Encouraging Response Rates in LGSOC

January 26, 2023 1:00 pm

by Jordyn Sava

With encouraging response rates and a well-tolerated safety profile seen in RAMP-201, experts are hopeful for the accelerated approval of avutometinib plus defactinib for low-grade serous ovarian cancer.

The combination of avutometinib (VS-6766) with defactinib (VS-6063), as … Read more

Acupuncture, acupressure may benefit women undergoing gynecologic cancer surgery

January 17, 2023 10:20 am

by Jennifer Southall

Women who underwent surgery for gynecologic cancers experienced decreased symptoms of anxiety and pain with the use of acupressure before surgery and acupuncture during surgery, according to study results published in Cancer.

Further investigation is needed … Read more

Targeting FRα Enters a New Era in Ovarian Cancer and Beyond

January 16, 2023 9:41 am

by Anita T. Shaffer

Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.Read more

COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer

January 12, 2023 10:08 am

by Ryan Scott

A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.

A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo)

Read more

Yale Cancer Center Research Helps Expand NCCN Guidelines for Ovarian Cancer

January 5, 2023 10:50 am

by Eliza Folsom

Results from a recent Yale Cancer Center Phase II trial studying ixabepilone and bevacizumab vs ixabepilone alone in platinum resistant ovarian cancer patients have led to the combination added as a Category 2B recommended regimen in Ovarian … Read more

FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer

November 18, 2022 11:51 am

by Jason Harris

The FDA has asked Clovis Oncology to limit use of rucaparib (Rubraca) to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.1

The company is considering the FDA’s request. If the 2 sides

Read more

FDA Requests Restriction of Second-line Maintenance Niraparib Indication in Ovarian Cancer

November 14, 2022 11:41 am

by Kristi Rosa

At the request of the FDA, GlaxoSmithKline (GSK) plc will restrict the second-line maintenance indication for niraparib (Zejula) to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA

Read more

Mirvetuximab Soravtansine Generates Improvement in PROs Vs Chemotherapy in Advanced Ovarian Cancer

October 13, 2022 2:03 pm

by Chris Ryan

Treatment with mirvetuximab soravtansine elicited a statistically significant benefit vs investigator’s choice of chemotherapy for the OV28 abdominal/gastrointestinal symptom subscale in patients with folate receptor alpha–positive, advanced ovarian cancer.

Treatment with mirvetuximab soravtansine elicited a statistically significant

Read more

Elizabeth Swisher, MD, on Predicting Therapy Benefits in Ovarian Cancer

October 5, 2022 4:42 pm

by Mark L. Fuerst

– KELIM score can now be used to look at upfront response, study showed

Tumor primary chemosensitivity testing can help determine if ovarian cancer patients need a boost along with first-line chemotherapy. In the VELIA trial, … Read more

Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancer

August 29, 2022 2:19 pm

by Charles Bankhead

Women with cardiovascular conditions (CVCs) and ovarian cancer had better 2-year survival if they received a nonselective beta blocker (NSBB) at or around the time of cancer surgery, a review of medical records showed.

Two-year postoperative survival … Read more

DS-6000a Displays Early Clinical Activity in Ovarian Cancer and RCC

August 24, 2022 2:20 pm

In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.

Interim data from a … Read more

Cure Rate After Chemotherapy in Stage III Ovarian Cancer

July 27, 2022 11:09 am

by Vicki Moore, PhD

Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured. The team detailed their findings in Gynecologic Oncology.

To determine what … Read more

ADCs Begin to Carve a Place in the Treatment Landscape for Ovarian Cancer

July 26, 2022 2:39 pm

by Brittany Lovely

Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates (ADCs) represent a promising development for this population.1

The treatment landscape for patients who experience disease progression

Read more

Epigenetic ‘Priming’ Boosts Cancer Immunotherapy

July 25, 2022 11:11 am

by Will Doss

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, making them more suitable for treatment with immunotherapy, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

This could … Read more

ASCO, ACCC Issue Recommendations to Boost Clinical Trial Diversity

July 24, 2022 10:44 am

by Jason Harris

The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) have issued a joint statement outlining 6 recommendations for boosting participation among underserved communities.1

Increasing the racial and ethnic diversity in

Read more

Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer

July 20, 2022 12:09 pm

by Caroline Seymour

The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the Read more

Farletuzumab Ecteribulin Shows Early Activity in Platinum-Resistant Ovarian Cancer

June 21, 2022 11:03 am

by Chris Ryan

The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.

The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in

Read more

Neoadjuvant Abemaciclib and Fulvestrant Facilitates High Complete Gross Resection Rate in Low-Grade Serous Cancer

June 15, 2022 12:04 pm

by Caroline Seymour

The combination of abemaciclib and fulvestrant led to encouraging responses when used as neoadjuvant therapy which translated to high complete gross resection rates in patients with advanced, low-grade serous ovarian, fallopian tube, and peritoneal carcinoma.

The combination

Read more